as a Federally Funded Research and Development Center 1993: The NIH Revitalization Act of 1993 encourages NCI to expand its efforts in prostate cancer, breast and other cancers which primarily or solely affected women, and authorized increased appropriations. 1998: Establishes the Office of Cancer Complementary and Alternative Medicine to study pseudoscientific alternative medicine treatments for cancer 2009: The American Recovery and Reinvestment Act of 2009 provided in additional funding for the NIH; the NCI received from that amount. 2016: The 21st Century Cures Act increased funding for biomedical research. The "Cancer Moonshot" program promised additional support for cancer research. On October 17, 2017, Norman Sharpless was sworn in as the 15th director of the National Cancer Institute. In April 2019, Sharpless left NCI to serve as the acting Commissioner of Food and Drugs. He returned to the institute in November 2019 as director. Anti-cancer drug investigations Organization The NCI is divided into several divisions and centers. Intramural Center for Cancer Research The CCR includes approximately 250 internal NCI research groups in Frederick and Bethesda. Division of Cancer Epidemiology and Genetics DCEG is made up of eight branches within the Trans-divisional Research Program. Extramural Division of Cancer Biology DCB oversees approximately 2000 grants per year in the areas of cancer cell biology; cancer immunology, hematology, and etiology; DNA and chromosome aberrations; structural biology and molecular applications; tumor biology and microenvironment; and tumor metastasis. "Special Research Programs" falling under the aegis of the DCB include: Physical Sciences-Oncology Network, Cancer Systems Biology Consortium, Oncology Models Forum, Barrett's Esophagus Translational Research Network, New Approaches to Synthetic Lethality for Mutant KRAS-Dependent Cancers, Molecular and Cellular Characterization of Screen-Detected Lesions, Fusion Oncoproteins in Childhood Cancers, and Cancer Tissue Engineering Collaborative. Division of Cancer Control and Population Sciences Division of Cancer Prevention Division of Cancer Treatment and Diagnosis DCTD supports eight research programs: The Biometric Research Program, The Cancer Diagnosis Program, The Cancer Imaging Program, The Cancer Therapy Evaluation Program, The Developmental Therapeutics Program, The Radiation Research Program, The Translational Research Program, and The Office of Cancer Complementary and Alternative Medicine. Division of Extramural Activities DEA processes and supports the thousands of grant applications NCI receives each year and compiles reports on the progress of research funded by the NCI's programs. Office of the director Center for Biomedical Informatics and Information Technology Center for Cancer Genomics CCG was created in 2011 and is responsible for management of